Related Experiment Video
Updated: Mar 3, 2026

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
Published on: October 6, 2016
The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development
Janessa M Smith1, Charles Flexner
1aDepartment of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland bDivisions of Clinical Pharmacology and Infectious Diseases, Department of Medicine Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract:
: It is estimated that by 2030 nearly three-quarters of persons living with HIV will be 50 years and older. The aging HIV population presents a new clinical concern for HIV providers: adverse effects from polypharmacy. An aging population means more comorbidities and potentially more drug-drug interactions for providers to manage. This review discusses major comorbidities including cardiovascular disease, anticoagulation, hypertension, diabetes mellitus and malignancy and considerations for drug-interactions with antiretrovirals.
More Related Videos
Related Concept Videos
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

